8-OH-PBZI
Systematic (IUPAC) name | |
---|---|
(3aS,9bR)-3-propyl-1,2,3a,4,5,9b-hexahydrobenzo[e]indol-8-ol | |
Clinical data | |
Identifiers | |
None | |
PubChem | CID 10353845 |
ChemSpider | 8529297 |
Chemical data | |
Formula | C15H21NO |
231.333 g/mol | |
SMILES
| |
| |
(what is this?) (verify) |
8-OH-PBZI is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D3 receptor.[1][2][3]
References
- ↑ Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N; Crider, AM; Ghosh, D; Cruse, SF; Fink-Jensen, A (1997). "The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain". European Journal of Pharmacology 339 (2–3): 261–70. doi:10.1016/S0014-2999(97)01372-1. PMID 9473144.
- ↑ Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). "Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI". European Journal of Pharmacology 342 (2–3): 153–61. doi:10.1016/S0014-2999(97)01494-5. PMID 9548380.
- ↑ Malik, P; Andersen, MB; Peacock, L (2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior 78 (4): 805–10. doi:10.1016/j.pbb.2004.05.019. PMID 15301939.